Actively Recruiting

Phase Not Applicable
Age: 4Years - 15Years
All Genders
ID07393165

The Effect of Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism

Led by Tanta University · Updated on 2026-02-06

40

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to study the effects of levothyroxine treatment on heart function in children aged 4 to 15 years with subclinical hypothyroidism, a condition marked by high thyroid-stimulating hormone (TSH) levels but normal thyroxine (T4). Subclinical hypothyroidism can impair heart function and increase various cardiovascular risks such as blood vessel problems and fluid around the heart. Children in the study are randomly assigned to one of two groups: one group will receive levothyroxine treatment starting at a dose of 2 micrograms per kilogram per day, with doses adjusted every 4 weeks to maintain normal TSH levels. The other group will receive no treatment. The study monitors the effects over a 3-month period after starting treatment. Participants will undergo assessments of heart function, specifically measuring the left ventricle's systolic function and fractional shortening three months after treatment begins. The study team will collect data on these heart measurements to evaluate how levothyroxine treatment might influence cardiac health in children with this thyroid condition. The total duration of participation is at least three months following treatment initiation.

CONDITIONS

Brief Title

Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism

Who Can Participate

Age: 4Years - 15Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age from 4 to 15 years
  • Both sexes
  • Stable elevated thyroid-stimulating hormone (TSH) of 4.5 mIU/L or higher with normal free T4 and FT3 in two measurements 4 to 6 weeks apart
Not Eligible

You will not qualify if you...

  • Overweight and obesity
  • Hypertension
  • Previous use of levothyroxine, antiepileptic drugs, or cardiac drugs within the last 6 months
  • Arrhythmia
  • Congenital or acquired heart disease
  • Liver or kidney disease
  • Hyperlipidemia
  • Diabetes
  • Infectious diseases
  • Respiratory diseases
  • Malignancies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 3 months

Participants receive L-thyroxine treatment with dose titration every 4 weeks until a normal thyroid-stimulating hormone (TSH) level is maintained, or participants receive no treatment if assigned to the control group.

Visits every 4 weeks during treatment

Trial Site Locations

Total: 1 location

1

Tanta University

Tanta, El-Gharbia, Egypt, 31527

Actively Recruiting

Loading map...

Research Team

Z

Zeinab E Elshareef, MBBCH

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Features of the Gut Microbiota in Patients With Critical Chr...

Essential Hypertension

Actively Recruiting

50 locations

An 18-month Open-label Study of Oral Finerenone with ACE Inh...

Chronic Kidney Disease

Actively Recruiting

179 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here